WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Officials of Endocyte Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for advanced ovarian cancer. Results were presented at the European Society of Gynaecologic Oncology meeting in Belgrade, Serbia. In 49 women with advanced-stage ovarian cancer, EC145 was shown to have anti-tumor activity in a significant percentage of trial participants.
